190 related articles for article (PubMed ID: 28743369)
1. Quality of life is significantly associated with survival in women with advanced epithelial ovarian cancer: An ancillary data analysis of the NRG Oncology/Gynecologic Oncology Group (GOG-0218) study.
Phippen NT; Secord AA; Wolf S; Samsa G; Davidson B; Abernethy AP; Cella D; Havrilesky LJ; Burger RA; Monk BJ; Leath CA
Gynecol Oncol; 2017 Oct; 147(1):98-103. PubMed ID: 28743369
[TBL] [Abstract][Full Text] [Related]
2. Does time interval between surgery and intraperitoneal chemotherapy administration in advanced ovarian cancer carry a prognostic impact? An NRG Oncology/Gynecologic Oncology Group study ancillary study.
Garcia-Soto AE; Java JJ; Nieves Neira W; Pearson JM; Cohn DE; Lele SB; Tewari KS; Walker JL; Alvarez Secord A; Armstrong DK; Copeland LJ
Gynecol Oncol; 2016 Dec; 143(3):484-489. PubMed ID: 27726923
[TBL] [Abstract][Full Text] [Related]
3. What is the role of retroperitoneal exploration in optimally debulked stage IIIC epithelial ovarian cancer? An NRG Oncology/Gynecologic Oncology Group ancillary data study.
Rungruang BJ; Miller A; Krivak TC; Horowitz NS; Rodriguez N; Hamilton CA; Backes FJ; Carson LF; Friedlander M; Mutch DG; Goodheart MJ; Tewari KS; Wenham RM; Bookman MA; Maxwell GL; Richard SD
Cancer; 2017 May; 123(6):985-993. PubMed ID: 27864921
[TBL] [Abstract][Full Text] [Related]
4. Should stage IIIC ovarian cancer be further stratified by intraperitoneal vs. retroperitoneal only disease?: a Gynecologic Oncology Group study.
Rungruang B; Miller A; Richard SD; Hamilton CA; Rodriguez N; Bookman MA; Maxwell GL; Krivak TC; Horowitz NS
Gynecol Oncol; 2012 Jan; 124(1):53-8. PubMed ID: 22032836
[TBL] [Abstract][Full Text] [Related]
5. Ascites predicts treatment benefit of bevacizumab in front-line therapy of advanced epithelial ovarian, fallopian tube and peritoneal cancers: an NRG Oncology/GOG study.
Ferriss JS; Java JJ; Bookman MA; Fleming GF; Monk BJ; Walker JL; Homesley HD; Fowler J; Greer BE; Boente MP; Burger RA
Gynecol Oncol; 2015 Oct; 139(1):17-22. PubMed ID: 26216729
[TBL] [Abstract][Full Text] [Related]
6. Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial.
Pignata S; Scambia G; Katsaros D; Gallo C; Pujade-Lauraine E; De Placido S; Bologna A; Weber B; Raspagliesi F; Panici PB; Cormio G; Sorio R; Cavazzini MG; Ferrandina G; Breda E; Murgia V; Sacco C; Cinieri S; Salutari V; Ricci C; Pisano C; Greggi S; Lauria R; Lorusso D; Marchetti C; Selvaggi L; Signoriello S; Piccirillo MC; Di Maio M; Perrone F; ; ; ; ;
Lancet Oncol; 2014 Apr; 15(4):396-405. PubMed ID: 24582486
[TBL] [Abstract][Full Text] [Related]
7. The survival detriment of venous thromboembolism with epithelial ovarian cancer.
Gunderson CC; Thomas ED; Slaughter KN; Farrell R; Ding K; Farris RE; Lauer JK; Perry LJ; McMeekin DS; Moore KN
Gynecol Oncol; 2014 Jul; 134(1):73-7. PubMed ID: 24793732
[TBL] [Abstract][Full Text] [Related]
8. Associations between p53 overexpression and multiple measures of clinical outcome in high-risk, early stage or suboptimally-resected, advanced stage epithelial ovarian cancers A Gynecologic Oncology Group study.
Darcy KM; Brady WE; McBroom JW; Bell JG; Young RC; McGuire WP; Linnoila RI; Hendricks D; Bonome T; Farley JH;
Gynecol Oncol; 2008 Dec; 111(3):487-95. PubMed ID: 18834621
[TBL] [Abstract][Full Text] [Related]
9. The prognostic effects of performance status and quality of life scores on progression-free survival and overall survival in advanced ovarian cancer.
Carey MS; Bacon M; Tu D; Butler L; Bezjak A; Stuart GC
Gynecol Oncol; 2008 Jan; 108(1):100-5. PubMed ID: 17920108
[TBL] [Abstract][Full Text] [Related]
10. Clinicopathologic characteristics associated with long-term survival in advanced epithelial ovarian cancer: an NRG Oncology/Gynecologic Oncology Group ancillary data study.
Hamilton CA; Miller A; Casablanca Y; Horowitz NS; Rungruang B; Krivak TC; Richard SD; Rodriguez N; Birrer MJ; Backes FJ; Geller MA; Quinn M; Goodheart MJ; Mutch DG; Kavanagh JJ; Maxwell GL; Bookman MA
Gynecol Oncol; 2018 Feb; 148(2):275-280. PubMed ID: 29195926
[TBL] [Abstract][Full Text] [Related]
11. Neutrophil-to-Lymphocyte Ratio and Platelet Count Predict Long-Term Outcome of Stage IIIC Epithelial Ovarian Cancer.
Zhou M; Li L; Wang X; Wang C; Wang D
Cell Physiol Biochem; 2018; 46(1):178-186. PubMed ID: 29587273
[TBL] [Abstract][Full Text] [Related]
12. Quality of life among long-term survivors of advanced stage ovarian cancer: A cross-sectional approach.
Lutgendorf SK; Shinn E; Carter J; Leighton S; Baggerly K; Guindani M; Fellman B; Matzo M; Slavich GM; Goodman MT; Tew W; Lester J; Moore KM; Karlan BY; Levine DA; Sood AK
Gynecol Oncol; 2017 Jul; 146(1):101-108. PubMed ID: 28527672
[TBL] [Abstract][Full Text] [Related]
13. The effect of older age on treatment outcomes in women with advanced ovarian cancer receiving chemotherapy: An NRG-Oncology/Gynecologic Oncology Group (GOG-0182-ICON5) ancillary study.
Sia TY; Tew WP; Purdy C; Chi DS; Menzin AW; Lovecchio JL; Bookman MA; Cohn DE; Teoh DG; Friedlander M; Bender D; Mutch DG; Gershenson DM; Tewari KS; Wenham RM; Wahner Hendrickson AE; Lee RB; Gray HJ; Secord AA; Van Le L; Lichtman SM
Gynecol Oncol; 2023 Jun; 173():130-137. PubMed ID: 37148580
[TBL] [Abstract][Full Text] [Related]
14. Prognostic impact of marital status on survival of women with epithelial ovarian cancer.
Mahdi H; Kumar S; Munkarah AR; Abdalamir M; Doherty M; Swensen R
Psychooncology; 2013 Jan; 22(1):83-8. PubMed ID: 21919121
[TBL] [Abstract][Full Text] [Related]
15. Predictive value of the Age-Adjusted Charlson Comorbidity Index on perioperative complications and survival in patients undergoing primary debulking surgery for advanced epithelial ovarian cancer.
Suidan RS; Leitao MM; Zivanovic O; Gardner GJ; Long Roche KC; Sonoda Y; Levine DA; Jewell EL; Brown CL; Abu-Rustum NR; Charlson ME; Chi DS
Gynecol Oncol; 2015 Aug; 138(2):246-51. PubMed ID: 26037900
[TBL] [Abstract][Full Text] [Related]
16. Quality of life of advanced ovarian cancer patients in the randomized phase III study comparing primary debulking surgery versus neo-adjuvant chemotherapy.
Greimel E; Kristensen GB; van der Burg ME; Coronado P; Rustin G; del Rio AS; Reed NS; Nordal RR; Coens C; Vergote I;
Gynecol Oncol; 2013 Nov; 131(2):437-44. PubMed ID: 23994107
[TBL] [Abstract][Full Text] [Related]
17. Prognostic significance of normal-sized ovary in advanced serous epithelial ovarian cancer.
Paik ES; Kim JH; Kim TJ; Lee JW; Kim BG; Bae DS; Choi CH
J Gynecol Oncol; 2018 Jan; 29(1):e13. PubMed ID: 29185271
[TBL] [Abstract][Full Text] [Related]
18. Clinical outcome and prognostic factors of patients with early-stage epithelial ovarian cancer.
Wei W; Li N; Sun Y; Li B; Xu L; Wu L
Oncotarget; 2017 Apr; 8(14):23862-23870. PubMed ID: 27852043
[TBL] [Abstract][Full Text] [Related]
19. Functional not chronologic age: Frailty index predicts outcomes in advanced ovarian cancer.
Kumar A; Langstraat CL; DeJong SR; McGree ME; Bakkum-Gamez JN; Weaver AL; LeBrasseur NK; Cliby WA
Gynecol Oncol; 2017 Oct; 147(1):104-109. PubMed ID: 28734497
[TBL] [Abstract][Full Text] [Related]
20. Quality of Life and Adverse Events: Prognostic Relationships in Long-Term Ovarian Cancer Survival.
Wenzel L; Osann K; McKinney C; Cella D; Fulci G; Scroggins MJ; Lankes HA; Wang V; Nephew KP; Maxwell GL; Mok SC; Conrads TP; Miller A; Mannel RS; Gray HJ; Hanjani P; Huh WK; Spirtos N; Leitao MM; Glaser G; Sharma SK; Santin AD; Sperduto P; Lele SB; Burger RA; Monk BJ; Birrer M
J Natl Cancer Inst; 2021 Oct; 113(10):1369-1378. PubMed ID: 33729494
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
